fat loss peptides: Frequently asked questions

Switch to a dual-receptor agonist like Survodutide if you've maintained stable weight for 8+ weeks despite continued dosing. The plateau typically reflects metabolic adaptation. Your body reduced NEAT and BMR to match the new caloric intake floor. Survodutide's glucagon receptor activation bypasses this adaptation by directly increasing hepatic thermogenesis and brown adipose tissue activity. Clinical data shows patients who plateau on semaglutide resume weight loss velocity within 4–6 weeks of switching to survodutide 6.0mg weekly.

Start with survodutide instead of mazdutide. It produces 85% of mazdutide's weight reduction with 14 percentage points lower nausea incidence. Extend dose titration to 20 weeks instead of the standard 16-week protocol, increasing by 0.5mg every 4 weeks instead of 1.0mg every 4 weeks. Eat smaller, lower-fat meals and avoid lying down within 2 hours of eating. If nausea persists beyond week 8 at therapeutic dose, Tesofensine offers a non-GLP-1 mechanism with 10.6% mean weight reduction and <20% nausea rates.

Choose a peptide with GIP receptor activity. Either tirzepatide (currently FDA-approved) or mazdutide (Phase III, available research-grade). GIP enhances insulin-mediated glucose uptake in skeletal muscle, maintaining protein synthesis during caloric deficit. Combine with resistance training 3× weekly and protein intake of 1.2–1.6g per kilogram of goal body weight. DEXA scans every 12 weeks confirm body composition changes. If lean mass loss exceeds 15% of total weight loss, increase protein intake and consider switching from a GLP-1 monotherapy to a GIP-containing dual- or triple-agonist.

Combine a GLP-1 agonist with a GH secretagogue protocol and prioritize resistance training. GLP-1 agonists produce rapid fat loss but can cause 20–30% of total weight loss to come from lean tissue if protein intake and training stimulus are inadequate. Adding CJC-1295/ipamorelin or MK 677 provides anabolic signaling that offsets muscle catabolism during caloric deficit. Aim for 1.6–2.2g protein per kg body weight daily and maintain progressive overload in the gym. Peptides amplify training adaptations but don't replace mechanical stimulus.

Skip GH secretagogues and focus on GLP-1 agonists or metabolic support peptides. If your IGF-1 level is above 200 ng/mL, adding a GH secretagogue won't produce meaningful additional fat loss and may increase side effect risk (joint stiffness, carpal tunnel symptoms, insulin resistance). Normal or elevated IGF-1 suggests that GH secretion isn't your limiting factor. Insulin resistance or caloric intake is. A GLP-1 agonist addresses both without elevating GH beyond physiological range.

Start with a GLP-1 receptor agonist like semaglutide or tirzepatide rather than a GH secretagogue. Elevated fasting insulin (above 10 µIU/mL) or HbA1c in the prediabetic range (5.7–6.4%) indicates insulin resistance as the primary driver of visceral fat accumulation. Exactly what GLP-1 agonists address mechanistically. Growth hormone secretagogues can theoretically worsen insulin resistance if baseline glucose control is poor, because GH opposes insulin action acutely. Clinical protocols typically reserve GH secretagogues for men with normal glucose metabolism who need lipolytic support.